N-glycosylation of disease-specific haptoglobin for the early screening of diabetic retinopathy.

IF 2.1 4区 生物学 Q3 BIOCHEMICAL RESEARCH METHODS
PROTEOMICS – Clinical Applications Pub Date : 2024-09-01 Epub Date: 2024-03-08 DOI:10.1002/prca.202300032
Zhonghao Yuan, Zhizhen Lai, Yixin Zhang, Jiyun Zhang, Jinyu Zhou, Dan Li, Weihong Yu, Jiang Zhou, Zhili Li
{"title":"N-glycosylation of disease-specific haptoglobin for the early screening of diabetic retinopathy.","authors":"Zhonghao Yuan, Zhizhen Lai, Yixin Zhang, Jiyun Zhang, Jinyu Zhou, Dan Li, Weihong Yu, Jiang Zhou, Zhili Li","doi":"10.1002/prca.202300032","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Diabetic retinopathy (DR), as one of the microvascular complications of diabetes, is a leading cause of acquired vision loss. Most DR cases are detected in the advanced stage through fundoscopy, making molecular biomarkers urgently needed for early diagnosis of DR.</p><p><strong>Experimental design: </strong>Serum disease-specific haptoglobin-β (Hp-β) chains of 100 patients with type 2 diabetes mellitus (T2DM) and 156 T2DM patients with non-proliferative diabetic retinopathy (NPDR) were separated using polyacrylamide gel electrophoresis. After in-gel digestion and enrichment, the intact N-glycopeptides were detected by mass spectrometry.</p><p><strong>Results: </strong>Fucosylation of Hp-β was significantly increased and sialylation of Hp-β was significantly decreased in background DR (BDR, an early-stage DR) patients compared with non-diabetic retinopathy patients (p < 0.05) and yielded area under curves (AUCs) of 0.801 and 0.829 in training and validation groups, respectively, which had an advantage over glycated hemoglobin A1c (AUC ≤ 0.691). Moreover, a significant increase in sialylated Hp-β was found in severe NPDR patients compared with BDR patients and yielded an AUC of 0.828 to distinguish severe NPDR from BDR.</p><p><strong>Conclusion: </strong>Changes in Hp-β glycosylation are closely related to DR, and may be used for early diagnosis and screening of DR.</p>","PeriodicalId":20571,"journal":{"name":"PROTEOMICS – Clinical Applications","volume":" ","pages":"e2300032"},"PeriodicalIF":2.1000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PROTEOMICS – Clinical Applications","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/prca.202300032","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/8 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Diabetic retinopathy (DR), as one of the microvascular complications of diabetes, is a leading cause of acquired vision loss. Most DR cases are detected in the advanced stage through fundoscopy, making molecular biomarkers urgently needed for early diagnosis of DR.

Experimental design: Serum disease-specific haptoglobin-β (Hp-β) chains of 100 patients with type 2 diabetes mellitus (T2DM) and 156 T2DM patients with non-proliferative diabetic retinopathy (NPDR) were separated using polyacrylamide gel electrophoresis. After in-gel digestion and enrichment, the intact N-glycopeptides were detected by mass spectrometry.

Results: Fucosylation of Hp-β was significantly increased and sialylation of Hp-β was significantly decreased in background DR (BDR, an early-stage DR) patients compared with non-diabetic retinopathy patients (p < 0.05) and yielded area under curves (AUCs) of 0.801 and 0.829 in training and validation groups, respectively, which had an advantage over glycated hemoglobin A1c (AUC ≤ 0.691). Moreover, a significant increase in sialylated Hp-β was found in severe NPDR patients compared with BDR patients and yielded an AUC of 0.828 to distinguish severe NPDR from BDR.

Conclusion: Changes in Hp-β glycosylation are closely related to DR, and may be used for early diagnosis and screening of DR.

用于早期筛查糖尿病视网膜病变的疾病特异性高铁血红蛋白的 N-糖基化。
目的:糖尿病视网膜病变(DR)是糖尿病微血管并发症之一,是导致后天性视力丧失的主要原因。大多数糖尿病视网膜病变都是在晚期通过眼底镜检查发现的,因此迫切需要分子生物标记物来早期诊断糖尿病视网膜病变:实验设计:使用聚丙烯酰胺凝胶电泳分离 100 名 2 型糖尿病(T2DM)患者和 156 名 T2DM 非增殖性糖尿病视网膜病变(NPDR)患者的血清特异性隐球蛋白-β(Hp-β)链。凝胶内消化和富集后,用质谱法检测完整的 N-糖肽:结果:与非糖尿病视网膜病变患者相比,背景 DR(BDR,早期 DR)患者 Hp-β 的岩藻糖基化明显增加,而 Hp-β 的硅烷基化则明显减少(p 结论:Hp-β糖基化的变化可能与糖尿病视网膜病变有关:Hp-β 糖基化的变化与 DR 密切相关,可用于 DR 的早期诊断和筛查。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
PROTEOMICS – Clinical Applications
PROTEOMICS – Clinical Applications 医学-生化研究方法
CiteScore
5.20
自引率
5.00%
发文量
50
审稿时长
1 months
期刊介绍: PROTEOMICS - Clinical Applications has developed into a key source of information in the field of applying proteomics to the study of human disease and translation to the clinic. With 12 issues per year, the journal will publish papers in all relevant areas including: -basic proteomic research designed to further understand the molecular mechanisms underlying dysfunction in human disease -the results of proteomic studies dedicated to the discovery and validation of diagnostic and prognostic disease biomarkers -the use of proteomics for the discovery of novel drug targets -the application of proteomics in the drug development pipeline -the use of proteomics as a component of clinical trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信